



# Global Burden of Disease: Implications for researchers in Sub-Saharan Africa

---

**Tom Achoki, MD**

**Director of African Initiatives**

**26<sup>th</sup> February 2016**

# Overview

---

- About IHME
- Global Burden of Disease; History and Current efforts
- Relevance to researchers in Africa
- Next steps

# Institute for Health Metrics and Evaluation

---

- Dedicated to providing independent, rigorous, and timely scientific measurements to accelerate progress on global health
- Focused on answering three critical questions:
  - What are the world's major health problems?
  - How well is society addressing these problems?
  - How do we best dedicate resources to get the maximum impact in improving population health in the future?
- Created in 2007 at the University of Washington

# IHME is bridging the gap


---

IHME is building the needed base of objective evidence about what works and what does not work to improve health conditions and the performance of health systems.

**AND...**It is making this evidence freely and readily available in the public domain.



# How do we achieve our goal of better health?



---

# Global Burden of Disease

# What is the Global Burden of Disease?

---

A **systematic scientific** effort to quantify the **comparative** magnitude of **health loss** due to diseases, injuries, and risk factors by age, sex, and geographies for specific points in time.

# The Global Burden of Disease:

## Underlying rationale

- Everyone deserves to live a long life in full health
- By providing a comprehensive picture of what **disables and kills** people across countries, time, ages, and sex
- We can understand what prevents us from achieving this goal



Photo: Susan Elden



# Why was the Global Burden of Disease created?



---

- Health system stewards lacked comprehensive information about major health problems in their countries, especially disabling causes
- Policymakers needed a way to compare the burden of different diseases and injuries
  - Before GBD, it was difficult for health officials to compare the burden of depression to cancer
  - GBD is a common currency used to compare the burden of fatal and non-fatal conditions

# Historical Context of GBD


# First GBD study

- Originated by the World Bank and WHO in 1991 to address these critical information gaps
- Preliminary results published in World Development Report 1993
- Final results published in two GBD volumes in 1996 and *The Lancet* in 1997
- Eight regions; 107 diseases; 10 risk factors
- Estimates for 1990 and projections to 2020



# Subsequent efforts


- GBD revisions for 1999, 2000, 2001, 2002, and 2004 published by WHO and World Bank
- National burden of disease studies conducted and published in 37 countries



# Current GBD Effort

# Global Burden of Disease 2010 Study

- Systematic attempt to quantify health loss from all major diseases, injuries, and risk factors for 187 countries over time from 1990 to 2010
  - 291 diseases and injuries
  - 1,160 sequelae of these diseases and injuries
  - 67 risk factors or clusters of risk factors
- GBD 2010 provided uncertainty intervals for all quantities of interest



# GBD 2010

- 488 authors from 50 countries; coordinated by the Institute for Health Metrics and Evaluation (IHME)
- Estimated premature death and disability from 291 diseases and injuries, 1,160 sequelae, and 67 risk factors
- Results for 20 age groups, 187 countries, and 21 regions
- First published in a dedicated issue of *The Lancet* in December 2012; results of study freely accessible online

## THE LANCET

Volume 380, Number 9553, Pages 2051-2265, December 15, 2012-January 6, 2013 www.thelancet.com


### The Global Burden of Disease Study 2010



The Lancet (ISSN 0950-2688) is published weekly except for the last issue in December which is a triple issue. It is owned by Elsevier Ltd. © 2012 Elsevier Ltd. All rights reserved. Elsevier Ltd's North American agent is Elsevier Inc., 627 Third Avenue South, New York, NY 10016-7500, USA. Tel: 212-633-2000. Fax: 212-633-2001. Periodical postage paid at New York, NY and additional mailing offices. # 955-980 USPS CDSN F449091017. POSTMASTER: Send address changes to The Lancet, Elsevier Customer Service Journals, 3251 River Street, Philadelphia, PA 19104, USA. The Lancet is a registered trademark of Elsevier Ltd. Printed in Great Britain. Printed on acid-free paper. (Printed on 100% recycled paper.)

### THE GLOBAL BURDEN OF DISEASE: GENERATING EVIDENCE, GUIDING POLICY

INSTITUTE FOR HEALTH METRICS AND EVALUATION UNIVERSITY OF WASHINGTON



# A global public good (GBD 2.0)

---

## Vision

- 1) Provide the world access to continuously updated country-level assessments of the burden of disease over time for all major diseases, injuries, and risk factors
- 2) Rapidly incorporate new evidence on descriptive epidemiology in GBD country, regional, and global estimates and make it widely available
- 3) Adopt methodological innovations or studies that provide new insights into etiology or causation when the evidence is compelling



# GBD 2013

---

- Covers 21 regions and 188 countries
- Incorporated critical feedback on the GBD 2010 estimates
- Drew on many new datasets proposed by disease, injury, and country experts
- Included subnational analyses of China, Mexico, and the UK
- Papers published on smoking, overweight and obesity, maternal and child mortality, causes of death, and HIV, tuberculosis, and malaria
- Collaborative effort of over 1,000 researchers in more than 100 countries, with IHME as the coordinating center



# Key aspects of GBD 2013

---

- 1) Expanding the collaborative network** – in addition to strengthening expert input in key disease, injury and risk factor areas, major emphasis on developing collaborators in each country.
- 2) Re-engineering of the code for GBD 2010** – improved computational efficiency, standardization across all analyses, automated archiving, linkage of data to the GHDx, allowing for sub-national estimation within the overall framework.
- 3) Improved estimation tools** – DisMod-MR 1.0 extensively used for GBD 2010. Version 2.0 is a major improvement: 100 times faster, more analyst control of modeling options, new visual interface, consistent posterior estimation for each country.

# Key aspects of GBD 2013

---

- 4) **Documenting sources used for GBD 2010** – many expert groups provided data input sheets with missing source documentation. Major effort to trace back sources and document them in the GHDx.
- 5) **Incorporating new studies and data** – Extending systematic reviews to 2013, adding new survey data sources, incorporating sources provided by new collaborators, major addition of more recent cancer registry data.
- 6) **Changes in estimation methods** for diarrhea etiologies and pneumonia etiologies.
- 7) **Enhanced transparency** of source data for each input – source metadata available for each outcome in GBD 2013 visualization tools consistent with data access policy.

# GBD Collaborators

---

- GBD 2010 collaboration organized around diseases, injuries and risk factors. GBD 2013 and 2015 have substantially expanded this collaboration.
- GBD now has collaborators, organized by country, whose roles are to:
  - Assess the face validity of country results.
  - Identify missing datasets or inadequate or incorrect interpretation of available data.
  - Interpret findings and facilitate country policy translation.
  - Where feasible, undertake sub-national assessments.


# GBD Collaborators

Currently, GBD 2015 has enrolled a total of 1,414 collaborators from 115 countries



# New data visualizations for GBD 2013

- Mortality Viz explains GBD modeling process and explores results, released December 2014.
- Life expectancy and probability of death, released December 2014.
- Cod Viz update, released December 2014.
- Tobacco, obesity, and MDG viz tools released in 2014.
- Epi Viz, released with YLD paper.
- New GBD Compare tool released with DALYs and risk factor papers.



# GBD 2015: Subnational estimation

- Mexico
- Great Britain
- China
- United States
- Brazil
- India
- Kenya
- Japan
- Sweden
- South Africa
- Saudi Arabia
- New Zealand



PUBLIC  
HEALTH  
FOUNDATION  
OF INDIA



Instituto Nacional  
de Salud Pública



IHME



UNIVERSITY of WASHINGTON

# Relevance to researchers in Africa



# How can we increase the value of GBD results?

---

- Obtain more data from regions or causes with missing data
- Involve Ministries of Health, other government actors in dissemination of results
- Increase engagement with policymakers by providing policy translation materials to turn results into action

# Why become a GBD Collaborator?

- Engage more fully in the GBD enterprise
  - Better understand GBD estimation
  - Provide feedback at earlier stages in the estimation and publication-writing processes
  - Learn about GBD analytic tools and data visualizations
- Connect and collaborate with colleagues in your field of expertise



# Areas of potential collaboration

---

- Research and technical support
  - Global Burden of Disease Technical Training Workshop
  - Collaboration on GBD studies
  - Ongoing opportunity to join study effort as a GBD Collaborator
- Policy dissemination and uptake
  - Possible collaboration to discuss findings and implications of GBD results for the country
- Monitoring progress and challenges in the country
  - Annual updates of GBD will provide insight into evolution of health trends in the country



# Next Steps

# Four easy steps

- Visit IHME website and get familiar with the GBD visualizations: <http://vizhub.healthdata.org/gbd-compare/#>
- Become a GBD collaborator by signing up here; <http://www.healthdata.org/gbd/call-for-collaborators>
- If you know someone who is using GBD data for decision making; nominate them for the Roux Prize: <http://www.healthdata.org/roux-prize>
- Get in touch with me at : [tachoki@uw.edu](mailto:tachoki@uw.edu)

# Thank You